Dirk R. Wijnen schreef:
Some analysts have questioned just how attractive Crucell would be to a bigger company, since it has extensive product and technology partnerships with many firms that would deprive an acquirer of certain programmes.
But Brus said he did not believe the existence of such alliances was an obstacle, pointing out that they were common in the biotech sector and could be overcome via settlements.
"If I was a pharmaceutical group looking at a company that had multiple partnerships, I would deal with it like AstraZeneca dealt with Cambridge Antibody Technology and its relationship with Abbott. I don't see that as a stumbling block," he said.
"The segment of vaccines and antibodies is attractive to every pharma company," he added.